JP2009539777A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539777A5 JP2009539777A5 JP2009513524A JP2009513524A JP2009539777A5 JP 2009539777 A5 JP2009539777 A5 JP 2009539777A5 JP 2009513524 A JP2009513524 A JP 2009513524A JP 2009513524 A JP2009513524 A JP 2009513524A JP 2009539777 A5 JP2009539777 A5 JP 2009539777A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- trimebutine
- nitroarginine
- demethylated
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LORDFXWUHHSAQU-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester Chemical compound C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 LORDFXWUHHSAQU-UHFFFAOYSA-N 0.000 claims description 19
- 229960005345 trimebutine Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 6
- 208000004998 Abdominal Pain Diseases 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 208000009935 visceral pain Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 28
- UMWBHGDTJNLDHJ-VWMHFEHESA-N (2S)-5-(diaminomethylideneamino)-2-nitramidopentanoic acid 4-hydroxybenzenecarbothioamide Chemical compound NC(=S)C1=CC=C(O)C=C1.NC(=N)NCCC[C@@H](C(O)=O)N[N+]([O-])=O UMWBHGDTJNLDHJ-VWMHFEHESA-N 0.000 claims 2
- IGDGSQZPIWOEGV-UHFFFAOYSA-N 2-carbamothioylbenzoic acid Chemical compound NC(=S)C1=CC=CC=C1C(O)=O IGDGSQZPIWOEGV-UHFFFAOYSA-N 0.000 claims 2
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- GVEVKAIAOIRIAL-UHFFFAOYSA-N 4-carbamothioylbenzoic acid Chemical compound NC(=S)C1=CC=C(C(O)=O)C=C1 GVEVKAIAOIRIAL-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 206010051153 Diabetic gastroparesis Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 230000017858 demethylation Effects 0.000 claims 1
- 238000010520 demethylation reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 5
- 239000002253 acid Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000016924 KATP Channels Human genes 0.000 description 2
- 108010053914 KATP Channels Proteins 0.000 description 2
- 102000008212 P-Selectin Human genes 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000050 smooth muscle relaxant Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JYNPQXKLKQHEFP-UHFFFAOYSA-N CCCCC1(C(C(=C(C(=C1C)C)C)NC)C(=O)O)C2=CC=CC=C2 Chemical compound CCCCC1(C(C(=C(C(=C1C)C)C)NC)C(=O)O)C2=CC=CC=C2 JYNPQXKLKQHEFP-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FSRLGULMGJGKGI-BTJKTKAUSA-N Trimebutine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 FSRLGULMGJGKGI-BTJKTKAUSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80406706P | 2006-06-06 | 2006-06-06 | |
| US60/804,067 | 2006-06-06 | ||
| PCT/CA2007/001008 WO2007140611A1 (en) | 2006-06-06 | 2007-06-06 | Salts of trimebutine and n-desmethyl trimebutine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539777A JP2009539777A (ja) | 2009-11-19 |
| JP2009539777A5 true JP2009539777A5 (https=) | 2010-12-24 |
| JP5421098B2 JP5421098B2 (ja) | 2014-02-19 |
Family
ID=38801016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009513524A Expired - Fee Related JP5421098B2 (ja) | 2006-06-06 | 2007-06-06 | トリメブチン及びｎ−脱メチル化トリメブチンの塩類 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20110144188A1 (https=) |
| EP (1) | EP2024323B1 (https=) |
| JP (1) | JP5421098B2 (https=) |
| KR (1) | KR20090021346A (https=) |
| CN (1) | CN101489986A (https=) |
| AU (1) | AU2007257174B2 (https=) |
| BR (1) | BRPI0712417A2 (https=) |
| CA (1) | CA2653869A1 (https=) |
| RU (1) | RU2008152751A (https=) |
| WO (1) | WO2007140611A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7741359B2 (en) * | 2005-05-27 | 2010-06-22 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| US7932286B2 (en) * | 2007-07-31 | 2011-04-26 | Martin Francois | Method for treating colonic viscerosensitivity and spasticity |
| FR2927076B1 (fr) * | 2008-01-31 | 2010-03-26 | Oroxcell | Derives de 2-amino-2-phenyl-alkanol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| EP2744487B1 (en) | 2011-08-15 | 2016-10-05 | Research Foundation Of The City University Of New York | No- and h2s- releasing compounds |
| IN2014DN08379A (https=) * | 2012-03-12 | 2015-05-08 | Gicare Pharma Inc | |
| WO2016044951A1 (en) * | 2014-09-25 | 2016-03-31 | The Hospital For Sick Children | Compositions and methods for enhancing hair growth, promoting skin regeneration, and wound healing |
| RU2752086C1 (ru) | 2020-04-27 | 2021-07-22 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Новое соединение [2-(диметиламино)-2-фенилбутил]-3,4,5-триметоксибензоата 4-метил-2н-хромен-2-он-7-илсульфат и его применение |
| CN114916547B (zh) * | 2021-12-06 | 2024-11-15 | 南京天秾生物技术有限公司 | 2,6-二氨基-3-甲基己酸作为植物免疫诱抗剂的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2460919A1 (fr) * | 1979-07-11 | 1981-01-30 | Prod Synthese Ste Indle | Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique |
| JPS57500432A (https=) * | 1980-03-20 | 1982-03-11 | ||
| US4412992A (en) * | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
| US4440763A (en) * | 1981-03-18 | 1984-04-03 | Block Drug Company, Inc. | Use of 4-aminosalicyclic acid as an anti-inflammatory agent |
| ZA825384B (en) * | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| US4751221A (en) * | 1985-10-18 | 1988-06-14 | Sloan-Kettering Institute For Cancer Research | 2-fluoro-arabinofuranosyl purine nucleosides |
| US5245080A (en) * | 1989-02-20 | 1993-09-14 | Jouveinal Sa | (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-N-propylamine, process for preparing it and its therapeutical use |
| US5811547A (en) * | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
| CA2204747C (en) | 1995-09-08 | 2009-05-05 | Elena Carceller | New azo derivatives of 5-aminosalicylic acid |
| SE9700934D0 (sv) * | 1997-03-14 | 1997-03-14 | Astra Ab | New formulation |
| WO1998048826A1 (en) * | 1997-04-30 | 1998-11-05 | Northwestern University | Inhibition of nitric oxide synthase by amino acids and dipeptides |
| SV2001000242A (es) * | 1999-12-23 | 2001-10-25 | Warner Lambert Co | Combinacion de trimebutina con un analgesico derivado del opio |
| EP1110549A1 (en) * | 1999-12-23 | 2001-06-27 | Warner-Lambert Company | Use of trimebutine for treating pain |
| EP1296943A1 (fr) * | 2000-05-05 | 2003-04-02 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) | Derives d'aminoacides et leur application a titre de medicaments |
| US6602915B2 (en) * | 2000-07-27 | 2003-08-05 | Rutgers, The State University Of New Jersey | Therapeutic azo-compounds for drug delivery |
| AU2001285489A1 (en) * | 2000-08-29 | 2002-03-13 | Nobex Corporation | 5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
| US6986901B2 (en) * | 2002-07-15 | 2006-01-17 | Warner-Lambert Company Llc | Gastrointestinal compositions |
| JP2005533101A (ja) * | 2002-07-10 | 2005-11-04 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | アロステリック阻害剤又はマトリックス金属タンパク質分解酵素−１３の、セレコキシブでもバルデコキシブでもないシクロオキシゲナーゼ−２の選択的阻害剤との組合せ物 |
| US20040213842A1 (en) * | 2003-01-30 | 2004-10-28 | Dynogen Pharmaceuticals, Inc. | Methods of treating gastrointestinal tract disorders using sodium channel modulators |
| EP1645288A1 (en) | 2004-10-07 | 2006-04-12 | CTG Pharma S.r.l. | New nuclear transcription factors regulators |
-
2007
- 2007-06-06 US US12/303,082 patent/US20110144188A1/en not_active Abandoned
- 2007-06-06 US US11/759,154 patent/US7666907B2/en not_active Expired - Fee Related
- 2007-06-06 BR BRPI0712417-1A patent/BRPI0712417A2/pt not_active IP Right Cessation
- 2007-06-06 AU AU2007257174A patent/AU2007257174B2/en not_active Ceased
- 2007-06-06 EP EP07719924A patent/EP2024323B1/en not_active Not-in-force
- 2007-06-06 WO PCT/CA2007/001008 patent/WO2007140611A1/en not_active Ceased
- 2007-06-06 CA CA002653869A patent/CA2653869A1/en not_active Abandoned
- 2007-06-06 JP JP2009513524A patent/JP5421098B2/ja not_active Expired - Fee Related
- 2007-06-06 RU RU2008152751/04A patent/RU2008152751A/ru unknown
- 2007-06-06 CN CNA2007800264544A patent/CN101489986A/zh active Pending
- 2007-06-06 KR KR1020087029794A patent/KR20090021346A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539777A5 (https=) | ||
| JP2009543811A5 (https=) | ||
| KR101493125B1 (ko) | 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체 | |
| WO2012090104A1 (en) | Methods and compositions for designing novel conjugate therapeutics | |
| WO2013000286A1 (zh) | 蟾毒配基衍生物及其制备方法、包含该衍生物的组合物、及其用途 | |
| JP2008542209A5 (https=) | ||
| KR20110017885A (ko) | 탄산염 프로드러그 및 그것의 사용 방법 | |
| WO2013029431A1 (zh) | 苯并二氮杂卓衍生物的托西酸盐及其多晶型、它们的制备方法和用途 | |
| JP5421098B2 (ja) | トリメブチン及びｎ−脱メチル化トリメブチンの塩類 | |
| JP2009543813A5 (https=) | ||
| CN105764909B (zh) | 用于治疗泛酸激酶相关神经变性(pkan)的稳定泛酰巯基乙胺衍生物及用于合成这样的化合物的方法 | |
| CN101822841B (zh) | 有机胺衍生物作为小分子药物脑靶向修饰基团的用途 | |
| JP2018138594A (ja) | オナプリストン多形体及び使用方法 | |
| WO2013168021A1 (en) | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders | |
| CN104244936A (zh) | 镇痛剂 | |
| Wang et al. | A facile di-acid mono-amidation strategy to prepare cyclization-activating mono-carboxylate transporter 1-targeting gemcitabine prodrugs for enhanced oral delivery | |
| JP6173352B2 (ja) | 筋萎縮性側索硬化症の治療方法 | |
| CN104284884A (zh) | 氟取代的(3r,4r,5s)-5-胍基-4-乙酰氨基-3-(戊烷-3-基氧基)环己烯-1-甲酸、它们的酯及它们的应用 | |
| CN108947859B (zh) | 胡黄连素二聚体类似物jja-d0的衍生物或其药学上可接受的盐、制法与用途 | |
| JP2013535438A5 (https=) | ||
| CN104470510A (zh) | 一种基于前列腺素的支气管松解药 | |
| US20020025926A1 (en) | Enantiomers of S-adenosyl-l-methionine | |
| WO2019023450A1 (en) | HERBOXIDIENE DERIVATIVES AND USES THEREOF | |
| CN103919770B (zh) | 一种含噻喃酮结构的姜黄素类似物s5在制备抗炎药物方面的应用 | |
| WO2018153352A1 (zh) | 七元环小檗碱类似物及其药物组合物在制备治疗血液肿瘤的药物中的应用 |